BA, an organic compound with the formula C
6H
5CH
2OH, is used as a solvent for inks, paints, lacquers, and epoxy resin coatings due to its polarity. It is also a precursor to a variety of esters, used in the soap, perfume, and flavor industries. In some medications, BA is added as the preservative and solvent, and, when injected into the body, it is normally oxidized to benzoic acid and conjugated with glycine in the liver, and then excreted as hippuric acid. Clinically, the previously adopted but nowadays abandoned use of 0.9% BA-preserved intravenous saline flush solutions in premature infants was reported to cause a fetal toxic syndrome, gasping syndrome, intraventricular hemorrhage, neurologic handicap, and even 16 neonatal deaths, due to the immature metabolizing function of the neonatal liver, leading to accumulation and prolonged detrimental effects of BA.
34 –37 BA was also found to cause neurotoxicity in some experimental animal studies, in which cisterna magna injection damaged the central nervous system in dogs, and intrathecal injection caused demyelination and axonal degeneration in the cauda equina of rats.
38,39 When BA-preserved TA was used for vitreoretinal diseases, it was presumed to contribute to noninfectious endophthalmitis in 1.1%–23.8% of patients after intravitreal injection.
40 –42 This was supported by two large-scale studies in which none of the patients developed ocular inflammation after intravitreal injection of BA-free TA suspension.
43,44 Because the vitreous cavity is a gel within a closed space without active venous or lymphatic drainage, we speculated that BA injected here may damage ocular tissues and induce the secretion of cytokines and inflammation within the eye. We therefore suggest removal of the vehicle before intraocular use of TA by any of the three methods, standstill/sedimentation, density-gradient centrifugation, or filtration, as previously described.
21 –23